NEU1 and cancer: Experimental studies have shown that OP and NMBR inhibitor BIM-23127 inhibits independent autophosphorylation of IRβ and IRS-1 in HTC-IR cells, blocking Neu-1-mediated transactivation of the IR, which may be used as a therapeutic target for cancer [112].